

ARD

Annals of the Rheumatic Diseases
The EULAR Journal

Editor

Leo van de Putte (The Netherlands)

Associate editors

Thomas Bardin (France)
Johannes Bijlsma (The Netherlands)
Gerd Burmester (Germany)

Bevrah Hahn (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)

Methodological adviser

Jaap Fransen (The Netherlands)

Editorial board

M Aringer (Austria)
P Bacon (UK)
F Berenbaum (France)
M Boers (The Netherlands)
D Boumpas (Greece)
B Bresnihan (Ireland)
H Capell (UK)
M Cutolo (Italy)
G Firestein (USA)
P Goupille (France)
E Gravallesse (USA)
W Gross (Germany)
F Guillemin (France)
G Herrero-Beaumont (Spain)
F Houssiau (Belgium)
T Huizinga (The Netherlands)
C Jorgensen (France)
G Kollias (Greece)
T Kvien (Norway)
M Leirisalo-Repo (Finland)
F Luijten (Belgium)
H-M Lorenz (Germany)
W Maslinski (Poland)
M Matucci Cerinic (Italy)

K Nishioka (Japan)
M Nurmohamed
(The Netherlands)
S Özen (Turkey)
T Pap (Germany)
E Pascual Gómez (Spain)
L Punzi (Italy)
L Rönnblom (Sweden)
B Rozman (Slovenia)
G Schett (Austria)
J Da Silva (Portugal)
H Schulze-Koops (Germany)
A So (Switzerland)
T Sokka (USA)
D Symmons (UK)
P-P Tak (The Netherlands)
A Tyndall (Switzerland)
A Tzioufas (Greece)
J Vencovsky (Czech Republic)
M Ward (USA)
M Weisman (USA)
H Yazici (Turkey)
Editor, *BMJ*

Advisory committee

W vd Berg (The Netherlands)
S Bombardieri (Italy)
F Breedveld (The Netherlands)
L Crofford (USA)
J-M Dayer (Switzerland)
M Doherty (UK)
M Dougados (France)
J Edmonds (Australia)
P Emery (UK)
D Furst (USA)
S Gay (Switzerland)
J Kalden (Germany)
E Keystone (Canada)
L Klareskog (Sweden)

P Lipsky (USA)
S Lohmander (Finland)
R Maini (UK)
E M Mola (Spain)
H Moutsopoulos (Greece)
J O'Dell (USA)
K Pavelka (Czech Republic)
J Rovensky (Slovakia)
Y Shoenfeld (Israel)
J Smolen (Austria)
W van Venrooy
(The Netherlands)
E Veys (Belgium)
A Wiik (Denmark)

Guidelines for authors and reviewers

Guidance for authors and reviewers can be found at <http://ard.bmj.com/fora>
All papers must be submitted via Bench>Press at www.submit-ard.bmj.com

Disclaimer

Annals of the Rheumatic Diseases is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Subscription information

See p iv
ISSN 0003-4967 (print); 1468-2060 (online)


Copyright

© 2007 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*

Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/fora/licence.dtl>

• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth

• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Double stains by direct fluorescein isothiocyanate-labelled anti-proteasome antibody HP903. See p 5

contents ARD

Volume 66 Number 1 January 2007

Editorials

- 1 A good year for European rheumatology *T K Kvien*
- 2 Clinical relevance of vertebral fractures *W F Lems*

Extended reports

- 5 Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells *E Feist, M Brychcy, G Hausdorf, B Hoyer, K Egerer, T Dörner, U Kuckelkorn, G-R Burmester*
- 12 Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability *A M Bertoli, M Fernández, G S Alarcón, L M Vilá, J D Reveille, for the LUMINA Study Group*
- 18 Cigarette smoking and the risk for cartilage loss and knee pain in men with knee osteoarthritis *S Amin, J Niu, A Guermazi, M Grigoryan, D J Hunter, M Clancy, M P LaValley, H K Genant, D T Felson*
- 23 Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndrome *J-E Gottenberg, F Aucouturier, J Goetz, C Sordet, I Jahn, M Busson, J-M Cayuela, J Sibilia, X Mariette*
- 28 Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study *S A Karvounaris, P I Sidiropoulos, J A Papadakis, E K Spanakis, G K Bertias, H D Kritikos, E S Ganotakis, D T Boumpas*
- 34 EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCIIT) *B Combe, R Landewe, C Lukas, H D Bolosiu, F Breedveld, M Dougados, P Emery, G Ferraccioli, J M W Hazes, L Klareskog, K Machold, E Martin-Mola, H Nielsen, A Silman, J Smolen, H Yazici*
- 46 Sex: a major predictor of remission in early rheumatoid arthritis? *K Forslind, I Hafström, M Ahlmén, B Svensson for the BARFOT Study Group*
- 53 Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? *S Capellino, B Riepl, L Rauch, P Angele, M Cutolo, R H Straub*
- 59 Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis *C Turesson, L T H Jacobsson, G Sturfelt, E L Matteson, L Mathsson, J Rönnelid*
- 65 Increased absence due to sickness among employees with fibromyalgia *M Kivimäki, P Leino-Arjas, L Kaila-Kangas, M Virtanen, M Elovainio, S Puttonen, L Keltikangas-Järvinen, J Pentti, J Vahtera*



www.publicationethics.org.uk

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

- 70 Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis
C Turesson, R L McClelland, T J H Christianson, E L Matteson
- 76 Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis
H Maradit-Kremers, P J Nicola, C S Crowson, K V Ballman, S J Jacobsen, V L Roger, S E Gabriel
- 81 A clinical tool to determine the necessity of spine radiography in postmenopausal women with osteoporosis presenting with back pain
C Roux, G Priol, J Fechtenbaum, B Cortet, S Liu-Léage, M Audran
- 86 Symptoms and radiographic osteoarthritis: not as discordant as they are made out to be?
R Duncan, G Peat, E Thomas, E Hay, I McCall, P Croft
- 92 Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic
L Heuft-Dorenbosch, R Landewé, R Weijers, H Houben, S van der Linden, P Jacobs, D van der Heijde
- 99 A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip
F P Luyten, P Geusens, M Malaise, L De Clerck, R Westhovens, F Raeman, D Vander Mijnsbrugge, L Mathy, J P Hauzeur, F De Keyser, F Van den Bosch
- 107 Progression of salivary gland dysfunction in patients with Sjögren's syndrome
J Pijpe, W W I Kalk, H Bootsma, F K L Spijkervet, C G M Kallenberg, A Vissink
- 113 Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis
P S Helliwell, G Porter, W J Taylor, for The CASPAR Study Group
-
- Concise reports**
- 118 Asporin repeat polymorphism in rheumatoid arthritis
B Torres, G Orozco, J R García-Lozano, J Oliver, O Fernández, M A González-Gay, A Balsa, A García, D Pascual-Salcedo, M A López-Nevot, A Núñez-Roldán, J Martín, M F González-Escribano
- 121 Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis
S Rantapää-Dahlqvist, K Boman, A Tarkowski, G Hallmans
- 124 A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor α inhibitors
Y Yazici, H Yazici
-
- EULAR/EUROPEAN NEWS**
- 128 EULAR online course on rheumatic diseases
J W J Bijlsma, R Buff
-
- Letters**
- 130 Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse
P D Ziakas, L S Poulou, S Giannouli, A G Tzioufas, M Voulgarelis
- 132 Consensus Dutch Health Assessment Questionnaire
M Boers, J W G Jacobs, T P M van Vliet Vlieland, P L C M van Riel
- 133 Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation
M K de Vries, G J Wolbink, S O Stapel, E R de Groot, B A C Dijkmans, L A Aarden, I E van der Horst-Bruinsma
- 134 Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor α agents
M U Martínez-Martínez, E Cuevas-Orta, G Reyes-Vaca, L Baranda, R González-Amaro, C Abud-Mendoza
- 136 Successful treatment of refractory neuro-Behçet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile
K Fujikawa, K Aratake, A Kawakami, T Aramaki, N Iwanaga, Y Izumi, K Arima, M Kamachi, M Tamai, M Huang, H Nakamura, Y Nishiura, T Origuchi, H Ida, K Eguchi
- 138 Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo
B Vander Cruyssen, F De Keyser, E Kruithof, H Mielants, F Van den Bosch
-
- 140 Forthcoming events